Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia

Hiromichi Akahori, Kazunori Shibuya, Masako Obuchi, Yoshito Nishizawa, Akio Tsuji, Koji Kabaya, Masaru Kusaka, Hideya Ohashi, Haruhiko Tsumura, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We examined the effects of recombinant human thrombopoietin (rhTPO) on myelosuppressive chemotherapy-induced thrombocytopenia in cynomolgus monkeys. After treatment with nimustine (ACNU) on day 0, the monkeys intravenously received rhTPO at a dose of 0.04, 0.2 or 1 μg/kg/d or monkey's serum once each day from day 1 to day 2.8. Administration of rhTPO reduced the severity of thrombocytopenia and accelerated the rate of platelet recovery in a dose-dependent fashion. Treatment with the highest rhTPO dose completely prevented thrombocytopenia and stimulated a marked increase in platelet counts over the normal values. Animals treated with ACNU also became neutropenic and slightly anaemic. Administration of rhTPO following ACNU treatment significantly improved neutropenia with increasing doses of rhTPO, but had no effect on anaemia. Compared to the control animals, rhTP0-treated animals exhibited no significant-changes in several serum parameters, C-reactive protein concentration and some blood coagulation profiles within the study period. These results suggest a therapeutic efficacy of rhTPO in improving chemotherapy-induced thrombocytopenia.

Original languageEnglish
Pages (from-to)722-728
Number of pages7
JournalBritish Journal of Haematology
Volume94
Issue number4
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Thrombopoietin
Thrombocytopenia
Primates
Nimustine
Drug Therapy
Haplorhini
Macaca fascicularis
Blood Coagulation
Therapeutics
Neutropenia
Serum
Platelet Count
C-Reactive Protein
Anemia
Reference Values
Blood Platelets

Keywords

  • Chemotherapy
  • Neutropenia
  • Primates
  • Thrombocytopenia
  • Thrombopoietin

ASJC Scopus subject areas

  • Hematology

Cite this

Akahori, H., Shibuya, K., Obuchi, M., Nishizawa, Y., Tsuji, A., Kabaya, K., ... Miyazaki, H. (1996). Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. British Journal of Haematology, 94(4), 722-728.

Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. / Akahori, Hiromichi; Shibuya, Kazunori; Obuchi, Masako; Nishizawa, Yoshito; Tsuji, Akio; Kabaya, Koji; Kusaka, Masaru; Ohashi, Hideya; Tsumura, Haruhiko; Kato, Takashi; Miyazaki, Hiroshi.

In: British Journal of Haematology, Vol. 94, No. 4, 1996, p. 722-728.

Research output: Contribution to journalArticle

Akahori, H, Shibuya, K, Obuchi, M, Nishizawa, Y, Tsuji, A, Kabaya, K, Kusaka, M, Ohashi, H, Tsumura, H, Kato, T & Miyazaki, H 1996, 'Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia', British Journal of Haematology, vol. 94, no. 4, pp. 722-728.
Akahori H, Shibuya K, Obuchi M, Nishizawa Y, Tsuji A, Kabaya K et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. British Journal of Haematology. 1996;94(4):722-728.
Akahori, Hiromichi ; Shibuya, Kazunori ; Obuchi, Masako ; Nishizawa, Yoshito ; Tsuji, Akio ; Kabaya, Koji ; Kusaka, Masaru ; Ohashi, Hideya ; Tsumura, Haruhiko ; Kato, Takashi ; Miyazaki, Hiroshi. / Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. In: British Journal of Haematology. 1996 ; Vol. 94, No. 4. pp. 722-728.
@article{ebe4a5a779744a7da3fc5d083b670832,
title = "Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia",
abstract = "We examined the effects of recombinant human thrombopoietin (rhTPO) on myelosuppressive chemotherapy-induced thrombocytopenia in cynomolgus monkeys. After treatment with nimustine (ACNU) on day 0, the monkeys intravenously received rhTPO at a dose of 0.04, 0.2 or 1 μg/kg/d or monkey's serum once each day from day 1 to day 2.8. Administration of rhTPO reduced the severity of thrombocytopenia and accelerated the rate of platelet recovery in a dose-dependent fashion. Treatment with the highest rhTPO dose completely prevented thrombocytopenia and stimulated a marked increase in platelet counts over the normal values. Animals treated with ACNU also became neutropenic and slightly anaemic. Administration of rhTPO following ACNU treatment significantly improved neutropenia with increasing doses of rhTPO, but had no effect on anaemia. Compared to the control animals, rhTP0-treated animals exhibited no significant-changes in several serum parameters, C-reactive protein concentration and some blood coagulation profiles within the study period. These results suggest a therapeutic efficacy of rhTPO in improving chemotherapy-induced thrombocytopenia.",
keywords = "Chemotherapy, Neutropenia, Primates, Thrombocytopenia, Thrombopoietin",
author = "Hiromichi Akahori and Kazunori Shibuya and Masako Obuchi and Yoshito Nishizawa and Akio Tsuji and Koji Kabaya and Masaru Kusaka and Hideya Ohashi and Haruhiko Tsumura and Takashi Kato and Hiroshi Miyazaki",
year = "1996",
language = "English",
volume = "94",
pages = "722--728",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia

AU - Akahori, Hiromichi

AU - Shibuya, Kazunori

AU - Obuchi, Masako

AU - Nishizawa, Yoshito

AU - Tsuji, Akio

AU - Kabaya, Koji

AU - Kusaka, Masaru

AU - Ohashi, Hideya

AU - Tsumura, Haruhiko

AU - Kato, Takashi

AU - Miyazaki, Hiroshi

PY - 1996

Y1 - 1996

N2 - We examined the effects of recombinant human thrombopoietin (rhTPO) on myelosuppressive chemotherapy-induced thrombocytopenia in cynomolgus monkeys. After treatment with nimustine (ACNU) on day 0, the monkeys intravenously received rhTPO at a dose of 0.04, 0.2 or 1 μg/kg/d or monkey's serum once each day from day 1 to day 2.8. Administration of rhTPO reduced the severity of thrombocytopenia and accelerated the rate of platelet recovery in a dose-dependent fashion. Treatment with the highest rhTPO dose completely prevented thrombocytopenia and stimulated a marked increase in platelet counts over the normal values. Animals treated with ACNU also became neutropenic and slightly anaemic. Administration of rhTPO following ACNU treatment significantly improved neutropenia with increasing doses of rhTPO, but had no effect on anaemia. Compared to the control animals, rhTP0-treated animals exhibited no significant-changes in several serum parameters, C-reactive protein concentration and some blood coagulation profiles within the study period. These results suggest a therapeutic efficacy of rhTPO in improving chemotherapy-induced thrombocytopenia.

AB - We examined the effects of recombinant human thrombopoietin (rhTPO) on myelosuppressive chemotherapy-induced thrombocytopenia in cynomolgus monkeys. After treatment with nimustine (ACNU) on day 0, the monkeys intravenously received rhTPO at a dose of 0.04, 0.2 or 1 μg/kg/d or monkey's serum once each day from day 1 to day 2.8. Administration of rhTPO reduced the severity of thrombocytopenia and accelerated the rate of platelet recovery in a dose-dependent fashion. Treatment with the highest rhTPO dose completely prevented thrombocytopenia and stimulated a marked increase in platelet counts over the normal values. Animals treated with ACNU also became neutropenic and slightly anaemic. Administration of rhTPO following ACNU treatment significantly improved neutropenia with increasing doses of rhTPO, but had no effect on anaemia. Compared to the control animals, rhTP0-treated animals exhibited no significant-changes in several serum parameters, C-reactive protein concentration and some blood coagulation profiles within the study period. These results suggest a therapeutic efficacy of rhTPO in improving chemotherapy-induced thrombocytopenia.

KW - Chemotherapy

KW - Neutropenia

KW - Primates

KW - Thrombocytopenia

KW - Thrombopoietin

UR - http://www.scopus.com/inward/record.url?scp=9544248772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544248772&partnerID=8YFLogxK

M3 - Article

C2 - 8826901

AN - SCOPUS:9544248772

VL - 94

SP - 722

EP - 728

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -